Evolving the Pharmaceutical Business Model to Enable Sustainable Growth
First written in FY2017-Q1. 16 of 21 entries say "Restated". Latest entry: FY2023-Q1.
No other company in this theme has enough history to compare yet.
- FY2023-Q1ReframedAnnual report
「Under the FY2023 management policy “Achieving a growth trend through the pursuit of originality,” we focused on increasing business speed as a key point of our business strategy and actively pursued (1) faster growth of our new-medicine portfolio, (2) expansion of the development pipeline, and (3) faster drug discovery.」
The priorities for evolving the pharmaceuticals business model were reorganized around increasing business speed and three initiatives. - FY2022-Q3RestatedAnnual report
「Under the FY2022 management policy “Discernment in pursuing originality,” we actively pursued faster growth of our new-medicine portfolio, expansion of the development pipeline, faster drug discovery, and stronger cost competitiveness.」
The Group continues to pursue the FY2022 Stage 3 priorities for evolving its pharmaceuticals business model. - FY2022-Q2RestatedAnnual report
「Under the FY2022 management policy “Discernment in pursuing originality,” we actively pursued faster growth of our new-medicine portfolio, expansion of the development pipeline, faster drug discovery, and stronger cost competitiveness.」
The Group continues to prioritize the new-medicine portfolio, development pipeline, drug-discovery speed, and cost competitiveness in Stage 3. - FY2022-Q1ReframedAnnual report
「Under the FY2022 management policy “Discernment in pursuing originality,” we actively pursued faster growth of our new-medicine portfolio, expansion of the development pipeline, faster drug discovery, and stronger cost competitiveness.」
The Stage 3 priorities were reorganized as faster growth of the new-medicine portfolio, development-pipeline expansion, faster drug discovery, and stronger cost competitiveness. - FY2021-Q3RestatedAnnual report
「Under the FY2021 management policy “Taking on the challenge of pursuing originality,” we are working on faster growth of our new-medicine portfolio, expansion of the development pipeline and drug-discovery projects, and stronger cost competitiveness as our business strategies.」
The Group continues to pursue the first-year Stage 3 priorities for evolving its pharmaceuticals business model. - FY2021-Q2RestatedAnnual report
「In FY2021, the first year of Stage 3, under the management policy “Taking on the challenge of pursuing originality,” we are actively pursuing faster growth of our new-medicine portfolio, expansion of the development pipeline and drug-discovery projects, and stronger cost competitiveness, striving to shift to a growth trend.」
The Group continues to prioritize the new-medicine portfolio, development pipeline, drug-discovery projects, and cost competitiveness in the first year of Stage 3. - FY2021-Q1ReframedAnnual report
「In FY2021, the first year of Stage 3, under the management policy “Taking on the challenge of pursuing originality,” we will actively pursue faster growth of our new-medicine portfolio, expansion of the development pipeline and drug-discovery projects, and stronger cost competitiveness, striving to shift to a growth trend.」
The evolution of the pharmaceuticals business model was translated into a first-year Stage 3 plan focused on the new-medicine portfolio, development pipeline, drug-discovery projects, and cost competitiveness. - FY2020ReframedAnnual report
「Under the new medium-term management plan “HOPE100－Stage 3－,” we have adopted “Achieving a growth trend through the pursuit of originality” as our statement and are pursuing business and organizational strategies.」
In Stage 3, the evolution of the pharmaceuticals business model is expressed as pursuing distinctive competitive strengths to achieve a growth trend. - FY2020-Q3RestatedAnnual report
「In our core prescription pharmaceuticals business, we regard the discovery of original innovative medicines with global competitiveness, the continuous creation of new medicines, and market creation through new medicines as our highest priorities and are focusing on these areas.」
The Group continues to treat original innovative medicines, continuous new-medicine creation, and market creation as the highest priorities for its pharmaceuticals business. - FY2020-Q1RestatedAnnual report
「In our core prescription pharmaceuticals business, we regard the discovery of original innovative medicines with global competitiveness, the continuous creation of new medicines, and market creation through new medicines as our highest priorities and are focusing on these areas.」
The Group continues to treat original innovative medicines, continuous new-medicine creation, and market creation as the highest priorities for its pharmaceuticals business. - FY2019RestatedAnnual report
「In the prescription pharmaceutical business, we are working to evolve the pharmaceutical business model to enable sustainable growth.」
The Group continues to position the evolution of its business model for sustainable growth as a core business strategy. - FY2019-Q3RestatedAnnual report
「In our core prescription pharmaceuticals business, we are pursuing, with greater speed than ever, the discovery of original innovative medicines for global markets, the continuous creation of new medicines, and market creation through new medicines.」
The Group continues to pursue original innovative medicines, continuous new-medicine creation, and market creation through the prescription pharmaceuticals business. - FY2019-Q2RestatedAnnual report
「In our core prescription pharmaceuticals business, we are pursuing, with greater speed than ever, the discovery of original innovative medicines for global markets, the continuous creation of new medicines, and market creation through new medicines.」
The Group continues to pursue original innovative medicines, continuous new-medicine creation, and market creation through the prescription pharmaceuticals business. - FY2019-Q1RestatedAnnual report
「In our core prescription pharmaceuticals business, we are pursuing, with greater speed than ever, the discovery of original innovative medicines for global markets, the continuous creation of new medicines, and market creation through new medicines.」
The Group continues to position the prescription pharmaceuticals business as the core of sustainable growth and pursue original innovative medicines, continuous product creation, and market creation. - FY2018RestatedAnnual report
「In the prescription pharmaceutical business, we are working to evolve the pharmaceutical business model to enable sustainable growth.」
The Group continues to position the evolution of its business model for sustainable growth as a core business strategy. - FY2018-Q3RestatedAnnual report
「In the prescription pharmaceuticals business, we are working to evolve our pharmaceuticals business model to enable sustainable growth.」
The Group continues to evolve its pharmaceuticals business model to support sustainable growth. - FY2018-Q2RestatedAnnual report
「In the prescription pharmaceuticals business, we are working to evolve our pharmaceuticals business model to enable sustainable growth.」
The Group continues to evolve its pharmaceuticals business model to support sustainable growth. - FY2017RestatedAnnual report
「In the prescription pharmaceuticals business, we are working to evolve our pharmaceuticals business model to enable sustainable growth.」
The Group continues to evolve its pharmaceuticals business model to support sustainable growth. - FY2017-Q3RestatedAnnual report
「In the prescription pharmaceuticals business, we are working to evolve our pharmaceuticals business model to enable sustainable growth.」
The Group continues to evolve its pharmaceuticals business model to support sustainable growth. - FY2017-Q2RestatedAnnual report
「In the prescription pharmaceuticals business, we are working to evolve our pharmaceuticals business model to enable sustainable growth.」
The Group continues to evolve its pharmaceuticals business model to support sustainable growth. - FY2017-Q1First statedAnnual report
「In the prescription pharmaceutical business, we are working to evolve the pharmaceutical business model to enable sustainable growth.」
Evolving the business model for sustainable growth in the prescription pharmaceutical business is identified as a strategic initiative.